Xipamide: Difference between revisions
No edit summary |
No edit summary |
||
| Line 56: | Line 56: | ||
| smiles = CC1=C(C(=CC=C1)C)NC(=O)C2=CC(=C(C=C2O)Cl)S(=O)(=O)N | | smiles = CC1=C(C(=CC=C1)C)NC(=O)C2=CC(=C(C=C2O)Cl)S(=O)(=O)N | ||
}} | }} | ||
__NOTOC__ | |||
{{SI}} | |||
{{CMG}} | |||
==Overview== | |||
'''Xipamide''' is a sulfonamide [[diuretic]] drug marketed by [[Eli Lilly and Company|Eli Lilly]] under the trade names '''Aquaphor''' (in Germany) and '''Aquaphoril''' (in Austria). It is used for the treatment of [[oedema]] and [[hypertension]]. | '''Xipamide''' is a sulfonamide [[diuretic]] drug marketed by [[Eli Lilly and Company|Eli Lilly]] under the trade names '''Aquaphor''' (in Germany) and '''Aquaphoril''' (in Austria). It is used for the treatment of [[oedema]] and [[hypertension]]. | ||
== Mechanism of | == Mechanism of Action == | ||
Like the structurally related [[thiazide diuretic]]s, xipamide acts on the kidneys to reduce [[sodium]] reabsorption in the [[distal convoluted tubule]]. This increases the [[osmolarity]] in the [[Lumen (anatomy)|lumen]], causing less water to be reabsorbed by the collecting ducts. This leads to increased urinary output. Unlike the thiazides, xipamide reaches its target from the peritubular side (blood side).<ref name="Austria-Codex" /> | Like the structurally related [[thiazide diuretic]]s, xipamide acts on the kidneys to reduce [[sodium]] reabsorption in the [[distal convoluted tubule]]. This increases the [[osmolarity]] in the [[Lumen (anatomy)|lumen]], causing less water to be reabsorbed by the collecting ducts. This leads to increased urinary output. Unlike the thiazides, xipamide reaches its target from the peritubular side (blood side).<ref name="Austria-Codex" /> | ||
| Line 85: | Line 90: | ||
The lowest effective dose is 5 mg. More than 60 mg have no additional effects.<ref name="Austria-Codex" /> | The lowest effective dose is 5 mg. More than 60 mg have no additional effects.<ref name="Austria-Codex" /> | ||
== Adverse | == Adverse Effects == | ||
*'''more than 1/10 of all patients'''<ref name="Austria-Codex" /> | *'''more than 1/10 of all patients'''<ref name="Austria-Codex" /> | ||
**[[hypokalaemia]], which can lead to nausea, muscular weakness or cramps, and [[ECG]] abnormities | **[[hypokalaemia]], which can lead to nausea, muscular weakness or cramps, and [[ECG]] abnormities | ||
| Line 129: | Line 134: | ||
On 17 July 2012, cyclist [[Fränk Schleck]] was removed from the [[Tour de France]] by his team [[RadioShack-Nissan]] after his A-sample returned traces of xipamide.<ref>{{cite news|author=Richard Williams in Pau |url=http://www.guardian.co.uk/sport/2012/jul/17/tour-de-france-frank-schleck |title=Frank Schleck tests positive for banned diuretic and is out of Tour |publisher=The Guardian |date= 17 July 2012|accessdate=2012-07-18 |location=London}}</ref> | On 17 July 2012, cyclist [[Fränk Schleck]] was removed from the [[Tour de France]] by his team [[RadioShack-Nissan]] after his A-sample returned traces of xipamide.<ref>{{cite news|author=Richard Williams in Pau |url=http://www.guardian.co.uk/sport/2012/jul/17/tour-de-france-frank-schleck |title=Frank Schleck tests positive for banned diuretic and is out of Tour |publisher=The Guardian |date= 17 July 2012|accessdate=2012-07-18 |location=London}}</ref> | ||
== References == | ==References== | ||
{{ | {{reflist|2}} | ||
[[Category:Diuretics]] | [[Category:Diuretics]] | ||
[[Category:Sulfonamides]] | [[Category:Sulfonamides]] | ||
[[Category:Cardiovascular Drugs]] | |||
[[Category:Drug]] | |||
Latest revision as of 01:21, 25 July 2014
 | |
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| Pregnancy category |
|
| Routes of administration | oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 95% |
| Protein binding | 98% |
| Metabolism | glucuronide (30%) |
| Elimination half-life | 5.8 to 8.2 hours |
| Excretion | renal (1/3) and biliary (2/3) |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C15H15ClN2O4S |
| Molar mass | 354.80 g/mol |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
|
WikiDoc Resources for Xipamide |
|
Articles |
|---|
|
Most recent articles on Xipamide |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Xipamide at Clinical Trials.gov Clinical Trials on Xipamide at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Xipamide
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Directions to Hospitals Treating Xipamide Risk calculators and risk factors for Xipamide
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Xipamide |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Xipamide is a sulfonamide diuretic drug marketed by Eli Lilly under the trade names Aquaphor (in Germany) and Aquaphoril (in Austria). It is used for the treatment of oedema and hypertension.
Mechanism of Action
Like the structurally related thiazide diuretics, xipamide acts on the kidneys to reduce sodium reabsorption in the distal convoluted tubule. This increases the osmolarity in the lumen, causing less water to be reabsorbed by the collecting ducts. This leads to increased urinary output. Unlike the thiazides, xipamide reaches its target from the peritubular side (blood side).[1]
Additionally, it increases the secretion of potassium in the distal tubule and collecting ducts. In high doses it also inhibits the enzyme carbonic anhydrase which leads to increased secretion of bicarbonate and alkalizes the urine.
Unlike with thiazides, only terminal renal failure renders xipamide ineffective.[2]
Uses
- cardiac oedema caused by decompensation of heart failure
- renal oedema, chronic renal disease (but not with anuria)
- hepatic oedema caused by cirrhosis
- ascites
- lymphoedema
- hypertension in combination with chronic renal disease
Pharmacokinetics
After oral administration, 20 mg of xipamide are resorbed quickly and reach the peak plasma concentration of 3 mg/l within an hour. The diuretic effect starts about an hour after administration, reaches its peak between the third and sixth hour, and lasts for nearly 24 hours.
One third of the dose is glucuronidized, the rest is excreted directly through the kidney (1/3) and the faeces (2/3). The total plasma clearance is 30-40 ml/min. Xipamide can be filtrated by haemodialysis but not by peritoneal dialysis.[2]
Dosage
Initially 40 mg, it can be reduced to 10–20 mg to prevent a relapse.[2]
The lowest effective dose is 5 mg. More than 60 mg have no additional effects.[1]
Adverse Effects
- more than 1/10 of all patients[1]
- hypokalaemia, which can lead to nausea, muscular weakness or cramps, and ECG abnormities
- 1/100 to 1/10
- hyponatraemia, which can lead to headache, nausea, drowsiness or confusion
- orthostatic hypotension
- initially increase of urea, uric acid and creatinine, which can lead to a gout attack in predisposed patients
- 1/1000 to 1/10,000
- allergic reactions of the skin
- hyperlipidaemia
- less than 1/10,000
Contraindications
- anuria
- praecoma and coma hepaticum
- hypovolemia, hyponatremia, hypokalemia
- hypercalcemia
- gout
- sulfonamide hypersensitivity
- pregnancy, lactation period[1][2]
Interactions
Not recommended combinations
- Xipamide lowers the renal clearance of lithium which can lead to lithium intoxication.[1] (This interaction is classified as medium.[3])
Combinations requiring special precautions
The product information requests special precautions for these combinations:[1]
- The antihypertensive effect can be increased by ACE inhibitors, barbiturates, phenothiazines, tricyclic antidepressants, alcohol, etc. (Classified as minor.[3])
- NSAIDs can reduce the antihypertensive and diuretic effects. Xipamide increases the neurotoxicity of high doses of salicylates. (Classified as minor.[3])
- Toxicity of cardiac glycosides is increased due to hypokalemia and hypomagnesemia.(Classified as minor.[3])
- Antiarrhythmic agents (classes Ia and III), phenothiazines and other antipsychotics increase the risk of torsade de pointes due to hypokalemia.
Interactions not included in the product information
- Xipamide can reduce the effect of antidiabetics. (Classified as minor.[3])
Banned use in sport
On 17 July 2012, cyclist Fränk Schleck was removed from the Tour de France by his team RadioShack-Nissan after his A-sample returned traces of xipamide.[4]
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 Jasek, W, ed. (2007). Austria-Codex (in German). 1 (2007/2008 ed.). Vienna: Österreichischer Apothekerverlag. pp. 600–603. ISBN 978-3-85200-181-4.
- ↑ 2.0 2.1 2.2 2.3 2.4 Dinnendahl, V, Fricke, U, ed. (2007). Arzneistoff-Profile (in German). 10 (21 ed.). Eschborn, Germany: Govi Pharmazeutischer Verlag. ISBN 978-3-7741-9846-3.
- ↑ 3.0 3.1 3.2 3.3 3.4 Klopp, T, ed. (2007). Arzneimittel-Interaktionen (in German) (2007/2008 ed.). Arbeitsgemeinschaft für Pharmazeutische Information. ISBN 978-3-85200-184-5.
- ↑ Richard Williams in Pau (17 July 2012). "Frank Schleck tests positive for banned diuretic and is out of Tour". London: The Guardian. Retrieved 2012-07-18.
- Pages with script errors
- CS1 maint: Unrecognized language
- CS1 maint: Multiple names: editors list
- Template:drugs.com link with non-standard subpage
- Drugs with non-standard legal status
- Articles with changed ChemSpider identifier
- Articles with changed EBI identifier
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles with changed InChI identifier
- Chemical articles with unknown parameter in Infobox drug
- Chemical pages without DrugBank identifier
- Drugboxes which contain changes to verified fields
- Diuretics
- Sulfonamides
- Cardiovascular Drugs
- Drug